The indirect costs of multiple sclerosis: systematic review and meta-analysis

References

• Weiland TJ, Jelinek GA, Marck CH, et al. Clinically significant fatigue: prevalence and associated factors in an international sample of adults with multiple sclerosis recruited via the internet. PLoS One 2015;10(2):e0115541
   PubMed Web of Science ®Google Scholar
• O’Connor P. Key issues in the diagnosis and treatment of multiple sclerosis. Neurology 2002;59(6 Suppl 3):S1-S33
   Google Scholar
• Rice CM, Kemp K, Wilkins A, et al. Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases. Lancet 2013;382:1204-13
   PubMed Web of Science ®Google Scholar
• Figueiredo J, Silva A, Cerqueira JJ, et al. MS Prevalence and Patients’ Characteristics in the District of Braga, Portugal. Neurol Res Int 2015;2015:895163
   PubMedGoogle Scholar
• Pugliatti M, Rosati G, Carton H, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006;13:700-22
   PubMed Web of Science ®Google Scholar
• Krol M, Brouwer W. How to estimate productivity costs in economic evaluations. PharmacoEconomics 2014;32:335-44
   PubMed Web of Science ®Google Scholar
• Malinowski KP, Kawalec P. The indirect costs of ankylosing spondylitis: systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res 2015;1-16
   Google Scholar
• Casado V, Gubieras L, Romero-Pinel L, et al. Cost of the diagnosis of multiple sclerosis. J Neurol 2009;256(Suppl 2):S126
   Google Scholar
• Jennum P, Wanscher B, Frederiksen J, et al. The socioeconomic consequences of multiple sclerosis: A controlled national. Eur Neuropsychopharmacology 2012;22(1):36-43
   PubMed Web of Science ®Google Scholar
• Asche CV, Ho E, Chan B, et al. Economic consequences of multiple sclerosis for Canadians. ActaNeurologicaScandinavica 1997;95(5):268-74
   Web of Science ®Google Scholar
• Henriksson F, Jonsson B. The economic cost of multiple sclerosis in Sweden in 1994. Pharmacoeconomics 1998;13(5 II):597-606
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life in multiple sclerosis in The Netherlands. Eur J Health Econ 2006;7(2 Suppl):S55-64
   Google Scholar
• Matschay A, Nowakowska E, Hertmanowska H, et al. Cost analysis of therapy for patients with multiple sclerosis (MS) in Poland. Pharmacol Rep 2008;60(5):632-44
   PubMed Web of Science ®Google Scholar
• Nikfar S, Kebriaeezadeh A, Dinarvand R, et al. Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments. DARU 2013;21(1):50
   PubMed Web of Science ®Google Scholar
• Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm 2007;13(3):245-61
   PubMed Web of Science ®Google Scholar
• Grima DT, Torrance GW, Francis G, et al. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler 2000;6:91-8
   PubMed Web of Science ®Google Scholar
• Birnbaum HG, Ivanova JI, Samuels S, et al. Economic impact of multiple sclerosis disease-modifying drugs in an employed population: Direct and indirect costs. Curr Med Res Opin 2009;25(4):869-77
   PubMed Web of Science ®Google Scholar
• Ivanova JI, Birnbaum HG, Samuels S, et al. The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US. Pharmacoeconomics 2009;27(8):681-91
   PubMed Web of Science ®Google Scholar
• Parise H, Laliberte F, Lefebvre P, et al. Direct and indirect cost burden associated with multiple sclerosis relapses: Excess costs of persons with MS and their spouse caregivers. J Neurol Sci 2013;330(1-2):71-7
   PubMed Web of Science ®Google Scholar
• Ysrraelit C, Caceres F, Villa A, et al. ENCOMS: Argentinian survey in cost of illness and unmet needs in multiple sclerosis. Arq Neuropsiquiatr 2014;72(5):337-43
   PubMed Web of Science ®Google Scholar
• Johansson E, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from France. MultScler 2012;18(2 Suppl):17-22
   Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Germany. MultScler 2012;18(2 Suppl):23-7
   Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Italy. MultScler 2012;18(2 Suppl):29-34
   Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Spain. MultScler 2012;18(2 Suppl):35-9
   Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from the United Kingdom. MultScler 2012;18(2 Suppl):41-5
   Google Scholar
• Noyes K, Bajorska A, Chappel A, et al. Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study. Neurology 2011;77(4):355-63
   PubMed Web of Science ®Google Scholar
• Rajagopalan K, Brook RA, Beren IA, et al. Comparing costs and absences for multiple sclerosis among US employees: Pre- and post-treatment initiation. Curr Med Res Opin 2011;27(1):179-88
   PubMed Web of Science ®Google Scholar
• Kwiatkowski A, Puyfaucon M, Pelzer J, et al. Economic costs, utility and social participation of patients with multiple sclerosis treated by natalizumab. Mult Scler 2012;18(4 Suppl 1):341
   Google Scholar
• Kwiatkowski A, Marissal JP, Pouyfaucon M, et al. Social participation in patients with multiple sclerosis: correlations between disability and economic burden. BMC Neurol 2014;14(1):115
   PubMedGoogle Scholar
• Kobelt G, Texier-Richard B, Lindgren P. The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions. Mult Scler 2009;15(6):741-51
   PubMed Web of Science ®Google Scholar
• Amato MP, Battaglia MA, Caputo D, et al. The costs of multiple sclerosis: A cross-sectional, multicenter cost-of-illness study in Italy. J Neurol 2002;249(2):152-63
   PubMed Web of Science ®Google Scholar
• BlahovaDusankova J, Kalincik T, Dolezal T, et al. Cost of multiple sclerosis in the Czech Republic: The COMS study. Mult Scler 2012;18(5):662-8
   PubMed Web of Science ®Google Scholar
• Casado V, Martinez-Yelamos S, Martinez-Yelamos A, et al. Direct and indirect costs of multiple sclerosis in BaixLlobregat (Catalonia, Spain), according to disability. BMC Health Serv Res 2006;6:143
   PubMed Web of Science ®Google Scholar
• Fogarty E, Walsh C, McGuigan C, et al. Direct and indirect economic consequences of multiple sclerosis in Ireland. Appl Health Econ Health Policy 2014;12(6):635-45
   PubMedGoogle Scholar
• Ganzinger U, Badelt C, Vass K, et al. Health care costs of multiple sclerosis in Austria. Cross-sectional study including quality of life. Nervenarzt 2004;75(10):1000-6
   PubMed Web of Science ®Google Scholar
• Karabudak R, Karampampa K, Caliskan Z. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: Results from Turkey. J Med Econ 2014;18(1):69-75
   PubMed Web of Science ®Google Scholar
• Orlewska E, Mierzejewski P, Zaborski J, et al. A prospective study of the financial costs of multiple sclerosis at different stages of the disease. Eur J Neurol 2005;12(1):31-9
   PubMed Web of Science ®Google Scholar
• Romero M, Arango C, Alvis N, et al. Costs of multiple sclerosis in Colombia. Value in Health 2011;14(5 Suppl):S48-50
   Google Scholar
• Karampampa K, Gustavsson A, Van Munster ETL, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in Multiple Sclerosis study: The costs and utilities of MS patients in the Netherlands. J Med Econ 2013;16(7):939-50
   PubMedGoogle Scholar
• Tyas D, Kerrigan J, Russell N, et al. The distribution of the Cost of Multiple Sclerosis in the UK: How Do Costs Vary by Illness Severity? Value Health 2007;10(5):386-9
   PubMed Web of Science ®Google Scholar
• Ivanova JI, Bergman RE, Birnbaum HG, et al. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. J Med Econ 2012;15(3):601-9
   PubMedGoogle Scholar
• Torabipour A, AslZ A, Majdinasab N, et al. A study on the direct and indirect costs of multiple sclerosis based on expanded disability status scale score in Khuzestan, Iran. Int J Prev Med 2014;5(9):1131-8
   PubMedGoogle Scholar
• Taylor B, McDonald E, Fantino B, et al. The cost of multiple sclerosis in Australia. J Clin Neurosci 2007;14(6):532-9
   PubMed Web of Science ®Google Scholar
• McCrone P, Heslin M, Knapp M, et al. Multiple sclerosis in the UK: Service use, costs, quality of life and disability. Pharmacoeconomics 2008;26(10):847-60
   PubMed Web of Science ®Google Scholar
• Reese JP, John A, Wienemann G, et al. Economic burden in a German cohort of patients with multiple sclerosis. Eur Neurol 2011;66(6):311-21
   PubMed Web of Science ®Google Scholar
• Bourdette DN, Prochazka AV, Mitchell W, et al. Health care costs of veterans with multiple sclerosis: implications for the rehabilitation of MS. Arch Phys Med Rehabil 1993;74
   PubMed Web of Science ®Google Scholar
• Svendsen B, Myhr KM, Nyland H, et al. The cost of multiple sclerosis in Norway. Eur J Health Econ 2012;13(1):81-91
   PubMed Web of Science ®Google Scholar
• Oleen-Burkey MK, Castelli-Haley J, Lage MJ, et al. Burden of a multiple sclerosis relapse: The patients perspective. Patient 2012;5(1):57-69
   PubMedGoogle Scholar
• Coleman CI, Roberts MS, Sidovar M. Mobility, indirect costs, and health-related quality of life in multiple sclerosis. Value Health 2012;15(4):A146
   Google Scholar
• Coleman CI, Sidovar MF, Roberts MS, et al. Impact of mobility impairment on indirect costs and health-related quality of life in multiple sclerosis. PLoS One 2013;8(1):e54756
   PubMed Web of Science ®Google Scholar
• Hu S, Pan F, Goh JW. Burden of multiple sclerosis (MS) in China. Value Health 2012;15(7):A676
   Google Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life for patients with multiple sclerosis in Belgium. Eur J Health Econ 2006;7(2 Suppl):S24-33
   Google Scholar
• Palmer AJ, Colman S, O’Leary B, et al. The economic impact of multiple sclerosis in Australia in 2010. Mult Scler 2013;19(12):1640-6
   PubMed Web of Science ®Google Scholar
• Psenkova M, Paluch A, Bielik J, et al. Health economics of sclerosis multiplex in Slovakia. Value Health 2011;14(7):A320
   Google Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in the United Kingdom. Eur J Health Econ 2006;7(2 Suppl):S96-S104
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Austria. Eur J Health Econ 2006;7(2 Suppl):S14-23
   Google Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Germany. Eur J Health Econ 2006;7(2 Suppl):S34-44
   Google Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Italy. Eur J Health Econ 2006;7(2 Suppl):S45-54
   Google Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Spain. Eur J Health Econ 2006;7(2 Suppl):S65-74
   Google Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Switzerland. Eur J Health Econ 2006;7(2 Suppl):S86-95
   Google Scholar
• Mocko P, Kawalec P. The indirect costs of multiple sclerosis associated with absenteeism in Poland. Value Health 2014;17(7):A528-9
   Google Scholar
• Amato MP. Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents. ExpertOpin.Pharmacother 2004;5(10):2115-26
   PubMed Web of Science ®Google Scholar
• Patwardhan MB, Matchar DB, Samsa GP, et al. Cost of multiple sclerosis by level of disability: a review of literature. Multiple Sclerosis 2005;11:232-9
   PubMed Web of Science ®Google Scholar
• Grudzinski AN, Hakim Z, Cox ER, et al. The economics of multiple sclerosis. Distribution of costs and relationship to disease severity. Pharmacoeconomics 1999;15(3):229-40
   PubMed Web of Science ®Google Scholar
• Orlewska E. Economic burden of multiple sclerosis: what can we learn from cost-of-illness studies? Expert Rev Pharmacoecon Outcomes Res 2006;6(2):145-54
   PubMedGoogle Scholar
• Naci H, Fleurence R, Birt J, et al. Economic burden of multiple sclerosis. Pharmacoeconomics 2010;28(5):363-79
   PubMed Web of Science ®Google Scholar
• Kolasa K. How much is the cost of multiple sclerosis - systematic review. Przegl.Epidemiol 2013;67:75-85
   PubMedGoogle Scholar
• Gubieras L, Casado V, Romero-Pinel L, et al. Cost of the relapse of multiple sclerosis in Spain. Value Health 2011;14(7):A320
   Google Scholar
• Whetten-Goldstein K, Sloan FA, Goldstein LB, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998;4(5):419-25
   PubMed Web of Science ®Google Scholar
• Henriksson F, Fredrikson S, Masterman T, et al. Costs, quality of life and disease severity in multiple sclerosis: A cross-sectional study in Sweden. Eur J Neurol 2001;8(1):27-35
   PubMed Web of Science ®Google Scholar
• Kobelt G, Lindgren P, Smala A, et al. Costs and quality of life in multiple sclerosis.An observational study in Germany. HEPAC Health Economics in Prevention and Care 2001;2(2):60-8
   Google Scholar
• Svensson J, Borg S, Nilsson P. Costs and quality of life in multiple sclerosis patients with spasticity. Acta Neurol Scand 2014;129(1):13-20
   PubMed Web of Science ®Google Scholar
• Yagudina R, Kulikov A, Litvinenko M. Multiple sclerosis in russian federation: Evaluation of social and economical burden in real clinical practice. Value Health 2012;15(7):A549
   Google Scholar
• Berg J, Lindgren P, Fredrikson S, et al. Costs and quality of life of multiple sclerosis in Sweden. Eur J Health Econ 2006;7(2 Suppl):S75-85
   PubMedGoogle Scholar
• Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006;66(11):1696-702
   PubMed Web of Science ®Google Scholar
• Ponzio M, Gerzeli S, Brichetto G, et al. Economic impact of multiple sclerosis in Italy: focus on rehabilitation costs. NeurolSci 2015;36:227-34
   Google Scholar
• Sobha Ltd- Luxury Villas. Available from: http://fxtop.com/en/inflation-calculator.php
   Google Scholar
• OECD. Stat includes data and metadata for OECD countries and selected non-member economies. Available from: http://stats.oecd.org/
   Google Scholar
• Available from: www.xe.com
   Google Scholar
• Econ Stats: The Economic Statistics and Indicators Database. Available from: http://www.economywatch.com/economic-statistics/
   Google Scholar